Mark Zipkin

Science writer and PR EIC. All opinions expressed are my own.

[Mark Zipkin @MarkZipkin]

Migrating to bluesky, find me there.

[Mark Zipkin @MarkZipkin]

@heyitsaj__ @AdamSandler No

[Mark Zipkin @MarkZipkin]

Big news on aducanumab/Abeta today, but as I wrote back in April, the field has very mixed feelings: https://t.co/QkzNNKoY2F

[Mark Zipkin @MarkZipkin]

My latest news feature for NBT: Fecal microbiota potentiate checkpoint inhibitors, unleash microbiome startups https://t.co/ZydTMGoygJ

[Mark Zipkin @MarkZipkin]

One of my clients, BioSpace, is running a really interesting webinar next week looking at the biopharma workplace post-pandemic. Check it out here: https://t.co/GPNr3PpHeM

[Mark Zipkin @MarkZipkin]

My latest feature: Achilles Therapeutics’ IPO Caps Investment Wave for Neoantigens on https://t.co/mrWN8Mz38v https://t.co/wFU7umWwlM

[Mark Zipkin @MarkZipkin]

New paper from U Cambridge team shows neural stem cells use EVs to transfer mitochondria, improved clinical efficacy in mouse model of MS: https://t.co/vNQnUtJx0T
EV-transfered mtDNA previously showed promise in cancer: https://t.co/MBabBu4r3W

[Mark Zipkin @MarkZipkin]

My first News Feature for Nature Aging, on aducanumab and the state of the Abeta hypothesis: https://t.co/QkzNNKoY2F

[Mark Zipkin @MarkZipkin]

My first piece for https://t.co/mrWN8Mz38v! Have European Investors Missed the Exosome ‘Gold Rush’?https://t.co/5C2An1fsYz

[Mark Zipkin @MarkZipkin]

My latest feature on exosomes: Leading Approaches to Extracellular Vesicle Therapies | BioSpace https://t.co/voQfV3D95u

[Mark Zipkin @MarkZipkin]

COVID-19 Vaccine News: Moderna Variant Vaccine Begins Human Testing, AZ Put on Hold in Denmark https://t.co/Mx4JRUSYVm

[Mark Zipkin @MarkZipkin]

CARB-X Places $22 Million Bet on Affinivax Staph Vaccine https://t.co/zqjtxnG7VG

[Mark Zipkin @MarkZipkin]

Seres to Discontinue Microbiome Cancer Clinical Program: https://t.co/LmjUpGJU0a

[Mark Zipkin @MarkZipkin]

The plot thickens: ​FDA Delays Decision for Biogen's Alzheimer's Drug Until June | BioSpace https://t.co/uduCvkVzYg #jobs

[Mark Zipkin @MarkZipkin]

My first BioSpace article!

Oncorus Pivots to Scale Up Manufacturing with New GMP Facility

https://t.co/Y1SDSWJRxO #jobs

[Mark Zipkin @MarkZipkin]

@vees @NihilSegniter I think the "magic" part is having the kids listen to anything they're asked to do. If it's just that it's served up by technology then I'm going to start texting instructions to my kids.

[Mark Zipkin @MarkZipkin]

My latest news feature: Genetic medicines find a heartbeat https://t.co/t09xjjRkCH

[Mark Zipkin @MarkZipkin]

What pharma thinks exosomes (and other EVs) are good for: https://t.co/yCpyen6RJX

[Mark Zipkin @MarkZipkin]

34 AGs call for ‘march-in’ rights on remdesivir: https://t.co/eyGouzZRYk

[Mark Zipkin @MarkZipkin]

Great coverage from @_Ktktktktk of yesterday's deal between Codiak and @Sarepta to nestle AAVs inside of exosomes: https://t.co/Giaqx5mt2S

Surprised this wasn't an ASO-exosome deal. @EvoxLtd announced one last week, and Codiak is presenting on their exoASO program @ AACR today.